InMed Appoints Paul Brennan as President & Chief Executive Officer
Vancouver, BC — September 03, 2015 – InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today, that Paul Brennan, a 25-year veteran of the life sciences industry has joined InMed as President & CEO, effective September 14, 2015. Mr. Brennan succeeds Craig Schneider who will remain on the board of directors.
Craig Schneider, Director, states, “We are extremely pleased that at this critical stage in the Company’s development, Mr. Brennan will be taking the helm of InMed and leading the Company through to its next clinical trials, financings and infrastructure buildout. Paul has extensive M&A, general management, financial, corporate and drug development expertise. We are fortunate to be under the leadership of an executive with broad global pharmaceutical development and commercialization experience with a proven track record of successfully bringing life science products to market on a global scale. We are pleased to bring his experience to bear on InMed’s operations as we make progress toward delivering meaningful therapies to underserved markets.”
Mr. Brennan was previously Senior Vice-President of Business Development at Arbutus Biopharma (formerly Tekmira Pharmaceuticals- NASDAQ). Previously he has held a number of senior management and consulting positions at biotech companies based in the U.S.and Canada. Mr. Brennan served as CEO of Altair Therapeutics, an emerging biopharmaceutical company based in San Diego, which focused on developing inhaled oligonucleotides for respiratory diseases. Prior to Altair, Mr. Brennan was Senior Vice President, Business Development at Aspreva Pharmaceuticals and was involved in the sale of Aspreva to Vifor Pharma for $915 million. Mr. Brennan was also employed at AnorMED where he held a number of roles including Acting President during which time he was involved in the sale of AnorMED to Genzyme for $580 million. Mr. Brennan has held senior positions in business development and regulatory affairs at AstraZeneca, where he worked in Sweden, the United Kingdom and Canada.
“I am excited for this opportunity and am excited to lead our talented and dedicated team. InMed’s corporate strategy, strong pipeline and innovative development programs, provides a solid basis for long-term value. I am passionate about our prospects, and look forward to working for the benefit of patients, physicians, and shareholders as we advance our products through the clinic and into the market to deliver innovative and efficacious products.”
Mr. Brennan earned his B.Sc. in Life Sciences and his M.Sc. in Physiology from Queen’s University, in Kingston, Ontario.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
For more information, visit www.inmedpharma.com
Contact: InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
T: 604.669.7207
E: craig@inmedpharma.com
Investors:
Chris Bogart
SVP, Corporate Strategy and Investor Relations
T: 604.669.7207
E: chris@inmedpharma.com
Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about Mr. Brennan acting as President and CEO of the Company; Mr. Schneider remaining on the board of directors; and the fundamental value drivers of the company. With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: Mr. Brennan’s continued ability to serve as President and CEO; Mr. Schneider’s continued ability to serve as a director; continued demand for InMed’s products; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: the possibility that Mr. Brennan will no longer be willing or able to serve as President and CEO; the possibility that Mr. Schneider will no longer be willing or able to serve as a director; InMed’s proprietary platform technology, product pipeline and accelerated development pathway may not return their expected level of value; and economic or market conditions may worsen.
A more complete discussion of the risks and uncertainties facing InMed is disclosed in InMed’s continuous disclosure filings with Canadian securities regulatory authorities at www.sedar.com. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
- Published in InMed Pharmaceuticals
InMed Pharmaceuticals Appoints New CEO
InMed Appoints Paul Brennan as President & Chief Executive Officer
InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today that Paul Brennan, a 25-year veteran of the life sciences industry, has joined InMed as President & CEO, effective September 14, 2015. Mr. Brennan succeeds Craig Schneider who will remain on the board of directors.
Craig Schneider, Director, states, “We are extremely pleased that at this critical stage in the Company’s development, Mr. Brennan will be taking the helm of InMed and leading the Company through to its next clinical trials, financings and infrastructure buildout. Paul has extensive M&A, general management, financial, corporate and drug development expertise. We are fortunate to be under the leadership of an executive with broad global pharmaceutical development and commercialization experience with a proven track record of successfully bringing life science products to market on a global scale. We are pleased to bring his experience to bear on InMed’s operations as we make progress toward delivering meaningful therapies to underserved markets.”
Mr. Brennan was previously Senior Vice-President of Business Development at Arbutus Biopharma (formerly Tekmira Pharmaceuticals – NASDAQ). Previously he has held a number of senior management and consulting positions at biotech companies based in the U.S.and Canada. Mr. Brennan served as CEO of Altair Therapeutics, an emerging biopharmaceutical company based in San Diego, which focused on developing inhaled oligonucleotides for respiratory diseases. Prior to Altair, Mr. Brennan was Senior Vice President, Business Development at Aspreva Pharmaceuticals and was involved in the sale of Aspreva to Vifor Pharma for $915 million. Mr. Brennan was also employed at AnorMED where he held a number of roles including Acting President during which time he was involved in the sale of AnorMED to Genzyme for $580 million. Mr. Brennan has held senior positions in business development and regulatory affairs at AstraZeneca, where he worked in Sweden, the United Kingdom and Canada.
“I am excited for this opportunity and am excited to lead our talented and dedicated team. InMed’s corporate strategy, strong pipeline and innovative development programs, provides a solid basis for long-term value. I am passionate about our prospects, and look forward to working for the benefit of patients, physicians, and shareholders as we advance our products through the clinic and into the market to deliver innovative and efficacious products.”
Mr. Brennan earned his B.Sc. in Life Sciences and his M.Sc. in Physiology from Queen’s University, in Kingston, Ontario.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
For more information, visit www.inmedpharma.com.
- Published in Blog, Business, Life Sciences, Medical Marijuana
InMed Pharma Starts Testing Drug Delivery System
InMed Commences Development of Proprietary Drug Delivery System
InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN)(OTCQB: IMLFF) is pleased to announce it has initiated testing of a novel nanoparticle based delivery system for INM-750 which will be used for clinical formulations. INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder (See NR News Release May 26, 2015 and August 6, 2015).
InMed’s development programs for transdermal delivery will use a nanoparticle-based delivery system. The delivery system underwent investigation in in vitro and in vivo animal models and further studies are being conducted based on the European norm “BS EN 13726-1: 2002” entitled test methods for wound dressings.
InMed anticipates commencing human proof of concept clinical studies of INM-750 in February, 2016 with initial data expected by Q3 2016 after which InMed will seek orphan drug designation for INM-750 with the US Food and Drug Administration (FDA).
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
For more information, visit www.inmedpharma.com.
- Published in Blog, Business, Life Sciences, Medical Marijuana
ACT360 Solutions Announces Financial Results for Quarter Ended June 30, 2015
VANCOUVER, BRITISH COLUMBIA–(Marketwired – Aug. 31, 2015) – ACT360 Solutions Ltd. (the “Company” or “ACT360 Solutions”) (TSX VENTURE:AKM), a global provider of Online Customer Acquisition software and services, announced its unaudited financial results for the quarter ended June 30, 2015. Results are in Canadian dollars and were prepared in accordance with International Financial Reporting Standards.
According to Vincent Wong, CEO of ACT360 Solutions, “The Company continued to invest in corporate development activities and engage with Asian partners for various potential transactions in the online customer acquisition industry. Our efforts were validated by the July 17, 2015 execution of the Memorandum of Understanding (‘MOU’) with Shanghai Shenhua Holdings Co., Ltd., Shanghai Sailing Weidu Capital Management Co., Ltd., and ECS Engineering Consulting Services Co., Ltd., (collectively ‘China Partners’).”
Under the terms of the MOU, the Company’s wholly-owned special situation investment division Newport Concept Corporation (“Newport”) and China Partners will jointly invest in digital media growth opportunities including acquisitions, joint ventures, and technology licensing. Newport’s role is to identify synergistic investment opportunities, conduct preliminary due diligence, manage transactions through to closing, co-invest and oversee the operations of portfolio companies outside of China.
Three Months Ended June 30, 2015 |
Three Months Ended June 30, 2014 |
|||||
Sales | $298,166 | $238,683 | ||||
Net Income (Loss) | ($207,847 | ) | ($82,355 | ) | ||
Earnings (Loss) per share | ($0.00 | ) | ($0.00 | ) |
The unaudited consolidated financial statements and Management Discussion and Analysis for the quarter ended June 30, 2015 are available at www.sedar.com.
About ACT360 Solutions Ltd.
ACT360 Solutions is a global provider of Online Customer Acquisition software and services. We acquire, manage, and build Online Customer Acquisition businesses that address the specific client acquisition needs of our customers in particular vertical markets.
FORWARD-LOOKING STATEMENTS: Except for statements of historical fact, all statements in this news release – including, without limitation, statements regarding future plans and objectives of ACT360 Solutions Ltd. – are forward-looking statements that are subject to various risks and uncertainties. Forward-looking statements are based on current expectations and analyses, including the effects of anticipated product, service, and distribution changes and the potential benefits of such efforts and activities on the Company’s results of operations in future periods. There can be no assurance that such statements will prove to be accurate; actual results and future events could differ materially from those anticipated in such statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
ACT360 Solutions Ltd.
Vincent Wong
President
(604) 638 1553
www.act360.com
- Published in ACT360 Solutions
DealNet Announces Key Executive Appointments
DealNet Announces Key Executive Appointments: Roy Murzello as SVP of Consumer Finance Business and Michael Hilmer as CEO
DealNet Capital Corp. (“DealNet” or the “Company”) (TSX VENTURE: DLS) is pleased to announce that it has named Mr. Roy Murzello, a Consumer Lending Veteran with 15 years of experience, as its Senior Vice President of Consumer Financial Services.
Mr. Murzello has spent the last 10 years as a Senior Leader at one of Canada’s largest providers of HVAC finance solutions. His various roles have included Director of Dealer Programs, where Mr. Murzello was directly responsible for leading and growing the dealer finance programs including HVAC leasing. In this role, he also led a large leasing business that was acquired and subsequently integrated into the core business. His prior experience includes Vice President for Citi Group managing a major credit card initiative, a Senior Underwriter Manager at GE Capital and Credit Manager at CIBC. Mr. Murzello has a Master of Business Administration degree from Simon Fraser University.
“Roy’s pedigree is synonymous with large scale finance book management and risk mitigation. His experience with acquiring and operating large scale finance books, underpinned by strong governance and risk management fits our growth plans perfectly”, stated Michael Hilmer, Chief Executive Officer of DealNet.
The Company also appointed Mr. Michael Hilmer as its permanent Chief Executive Officer. Mr. Hilmer is a co-founder of DealNet and has served as the Company’s Interim CEO since March.
“Michael has performed at an exceptional level as Interim CEO and has earned our full confidence that he is the best choice for the CEO role” says Dr. Steven Small, Executive Chairman of the Corporation.
About DealNet Capital Corp.
DealNet is a consumer finance company that is initially focused on home improvement finance solutions including heating ventilation and air conditioning financing and leasing. DealNet leverages its large scale customer service and engagement technology platform to attract home improvement dealers by providing front and back office services to them resulting in dealer origination growth.
InMed Appoints Paul Brennan to the Board of Directors
InMed Pharmaceuticals Inc. (“InMed” or “the Company”) (CSE: IN)(OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based therapies combined with innovative drug delivery systems, announced today the appointment of Paul Brennan to the Company’s Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States.
Mr. Brennan is currently Senior Vice-President of Business Development at Arbutus Biopharma (formerly Tekmira Pharmaceuticals). Previously he has held a number of senior management and consulting positions at biotech companies based in the U.S.and Canada. Mr. Brennan served as CEO of Altair Therapeutics, an emerging biopharmaceutical company based in San Diego, which focused on developing inhaled oligonucleotides for respiratory diseases. Prior to Altair, Mr. Brennan was Senior Vice President, Business Development at Aspreva Pharmaceuticals and was involved in the sale of Aspreva to Vifor Pharma for $915 million. Mr. Brennan was also employed at AnorMED where he held a number of roles including Acting President during which time he was involved in the sale of AnorMED to Genzyme for $580 million. Mr. Brennan has held senior positions in business development and regulatory affairs at AstraZeneca, where he worked in Sweden, the United Kingdom and Canada.
“Paul’s extensive experience in the pharmaceutical and biotechnology industries, including senior leadership and board positions in several successful companies, will greatly complement and strengthen our Board,” said Craig Schneider, President and CEO of InMed. “We are delighted that he has accepted a position to the Board.”
Mr. Brennan earned his B.Sc. in Life Sciences and his M.Sc. in Physiology from Queen’s University, in Kingston, Ontario.
InMed also wishes to announce it has accepted the resignation of Kevin Puil as a Director of the Company, effective today. The Board wishes to thank Mr. Puil for his efforts on behalf of the Company.
About InMed
InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
For more information, visit www.inmedpharma.com.
- Published in Blog, Business, Life Sciences, Medical Marijuana
Progressively repurpose cutting-edge models
Seamlessly orchestrate process-centric best practices with end-to-end catalysts for change. Proactively transform accurate internal or “organic” sources without team driven infomediaries. Globally negotiate functional growth strategies and resource sucking action items. Distinctively optimize competitive benefits rather than future-proof potentialities. Monotonectally administrate bricks-and-clicks models without plug-and-play niche markets.
Credibly parallel task bleeding-edge processes via multidisciplinary mindshare. Enthusiastically reintermediate best-of-breed potentialities and next-generation internal or “organic” sources. Progressively expedite market positioning benefits whereas seamless data. Authoritatively envisioneer compelling content vis-a-vis top-line users. Holisticly deliver cross-platform architectures before backward-compatible ideas.
Conveniently pursue e-business platforms through viral results. Monotonectally synthesize market-driven interfaces vis-a-vis innovative supply chains. Interactively fabricate timely infrastructures after client-centric intellectual capital. Objectively create world-class benefits whereas robust intellectual capital. Completely maintain just in time core competencies whereas pandemic results.
Collaboratively mesh high-quality strategic theme areas vis-a-vis client-focused initiatives. Uniquely.
- Published in Mobile, Networking
Enthusiastically administrate ubiquitous
Competently leverage other’s high standards in customer service after superior web-readiness. Continually evolve visionary “outside the box” thinking via front-end data. Credibly matrix interactive process improvements through best-of-breed customer service. Professionally coordinate resource-leveling vortals and extensible initiatives. Credibly enable accurate ROI rather than premium experiences.
Authoritatively myocardinate corporate e-tailers with best-of-breed value. Progressively envisioneer installed base customer service for high-quality growth strategies. Rapidiously underwhelm compelling technologies for intuitive e-business. Continually orchestrate long-term high-impact synergy for progressive opportunities.
- Published in Mobile
Amana Copper (AMA:CSE) hires Momentum for IR
AMANA PROVIDES TRANSACTION UPDATE
Amana Copper Ltd. (AMA:CSE) is providing shareholders with an update on the company’s transaction with International Wastewater Systems (IWS), previously announced on June 5, 2015.
Amana and IWS are working diligently toward completion of the transaction. In preparation for closing the transaction, the company has reserved the stock symbol IWS with the Canadian Securities Exchange.
The company further announces that it has engaged Momentum Public Relations (MomentumPR) to provide investor and public relations services commencing Sept. 1, 2015. MomentumPR will assist the company in increasing public awareness by managing corporate communications and marketing activities, and facilitating dialogue with shareholders, the investment community and media contacts.
Max Gagne, president of MomentumPR, commented: “We are excited to team up with Amana and IWS, as they near completion of their proposed transaction. IWS is a world leader in state-of-the-art waste water heat recovery technology, with tremendous potential for revenue growth. MomentumPR has a particular focus on revenue-generating opportunities; we expect that IWS will be very well received by the investment community and will create great opportunities for our networks.”
ACT360 Solutions Announces Amendment to Private Placement
VANCOUVER, BRITISH COLUMBIA–(Marketwired – Aug. 7, 2015) –
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
ACT360 Solutions Ltd. (the “Company”) (TSX VENTURE:AKM) announces that further to its news release dated June 24, 2015, the Company has extended the closing of its proposed private placement (the “Offering”) and amended the terms of the units proposed to be issued thereunder.
The TSX Venture Exchange has granted the Company an extension for the filing of final material with respect to the Offering to September 8, 2015. It is anticipated the Company will close the Offering on or before this date.
The Offering will consist of up to 6,250,000 units (each, a “Unit”) of the Company at a price of $0.08 per Unit for gross proceeds of up to $500,000. Each Unit consists of one common share of the Company and one common share purchase warrant (a “Warrant”), each Warrant entitling the holder to purchase one common share of the Company at a price of $0.38 per share for a period of 24 months.
All other terms of the private placement previously announced remain unchanged.
About ACT360 Solutions Ltd.
ACT360 Solutions is a global provider of Online Customer Acquisition software and services. We acquire, manage, and build Online Customer Acquisition businesses that address the specific client acquisition needs of our customers in particular vertical markets.
FORWARD-LOOKING STATEMENTS: Except for statements of historical fact, all statements in this news release – including, without limitation, statements regarding future plans and objectives of ACT360 Solutions Ltd. – are forward-looking statements that are subject to various risks and uncertainties. Forward-looking statements are based on current expectations and analyses, including the effects of anticipated product, service, and distribution changes and the potential benefits of such efforts and activities on the Company’s results of operations in future periods. There can be no assurance that such statements will prove to be accurate; actual results and future events could differ materially from those anticipated in such statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
ACT360 Solutions Ltd.
Vincent Wong
President
(604) 638-1553, ext. 1
www.act360.com
- Published in ACT360 Solutions